Science World Journal of Cancer Science and Therapy

Editor Name: Enrique Alberto Diaz Cantin

Country: Argentina

University: Molecular Oncology, University Carlos III. Madrid Spain

Designation: Assistant Professor

Department: Molecular Oncology

Email: eadc64@gmail.com

BIOGRAPHY:

TEACHER TRAINING CAREER

Mastery: Yes. Molecular Oncology European School of Oncology. CNIO

Specialization: Yes, Clinical Oncology

Faculty: Assistant Professor CEMIC University Institute (IUC), 2002

Coordinator of the Specialist Career in Oncology. CEMIC University Institute (IUC). 2013

CERTIFICATIONS

1. Internist Doctor Certificate, National Academy of Medicine, 1998.

2. Clinical Oncologist Certificate, Municipality of the City of Buenos Aires, Year 2000.

3. Educational Commission for Foreign Medical Graduates (ECFMG)

4. Revalidation of the Medical Degree for the USA, 1991.

5. European Society of Medical Oncology (ESMO) Certification of the Oncologist Degree for Europe.

MEMBERSHIPS IN SCIENTIFIC SOCIETIES

1. American Society of Clinical Oncology (Full Member). 1995-present

2. European Society for Medical Oncology (Certified Regular Member) Title awarded by exam 2000; 2008; 2016 Valid until 2021

3. Argentina Society of Mastology (Regular Member) 2017-present

4. Argentina Association of Integrative Oncology (ASOI). Founding Member (Former member)

5. Cardio-Oncology Association of the Argentine Republic (ACORA). Member of the Board of Directors (Regular Member). 2017-present

MEDICAL RELATIONS:

1. 1992-present Center for Medical Education and Clinical Research, "Norberto Quirno" (CEMIC) University Institute, Staff Physician Department of Medical Clinic.

2. 1996-present Center for Medical Education and Clinical Research "Norberto Quirno" (CEMIC) University Institute Staff Physician of the Department of Medical Oncology.

3. 1996-present Mater Dei Sanatorium-University of Buenos Aires Staff Physician of the Department of Medical Oncology.Â

4. 2005-present FUNDALEU Boss Clinical Oncology

5. 2007-present Member of the International Advisory Board (â€œAdvisory Boardâ€) La Roche Hoffmann Laboratories Basel Switzerland

6. 2012-present CEMIC / CEMIC University Institute, Coordinator Specialist Career in Clinical Oncology

7. 2017-present Oncology Advisor BioSidus Laboratory

8. 2000-2002 CEMIC University Institute, Department of Internal Medicine, Research Coordinator

9. 2003-2012 Pavlovsky Hematology and Oncology Center, Coordinator, Clinical Oncology

Current participation in research projects

Evaluation of biomarkers of complete pathological response in patients with Her2 + breast cancer undergoing neoadjuvant therapy with chemotherapy + trastuzumab and pertuzumab.

Original work

2016-2018

Principal investigator

Results: Preliminary

Subsidy: YES National Cancer Institute

TDM1 in advanced breast cancer Her2 + previously treated with trastuzumab. CAMILLA multicenter study.

Principal Investigator by the Institution

Results: Preliminary

Subsidy: YES Roche Laboratories

Phase III study of Ribociclib vs placebo + fulvestrant in advanced breast cancer in 2nd line.

MONALEESA multi-center study

Principal Investigator by the Institution

Subsidy: Yes. Novartis laboratory.

Prospective evaluation of molecular markers in patients with advanced lung adenocarcinoma. PUL-003 Study

Study conducted at CEMIC

Co-investigator

Results: Yes

Subsidy: Yes

Prospective evaluation of molecular markers in patients with advanced and localized lung adenocarcinoma. PUL-006 Study

Study conducted at CEMIC and Roffo Hospital

Co-investigator

Results: No

Subsidy: Yes

PUBLICATIONS:

1. Pazdur R, Lassere Y, Diaz-CantÃ³n E, et al: Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule- dependent toxicities. Anti-Cancer Drugs (7); 1-6, 1996.

2. Diaz-CantÃ³n E, Pazdur R: Tratamiento MÃ©dico del Cancer Colorectal: Presente y Futuro: Medicina (Buenos Aires), 1996; 56:414-422.

3. Diaz-Canton E, Pazdur R: Adjuvant Medical Treatment for Colorectal Cancer: SurgicalÂ Clinics of North America, Volume 77, Number 1, pp 211-227,Â February 1997 .

4. Pazdur R, Lassere Y, Diaz-CantÃ³n E, et al: Phase I trial of Uracil-Tegafur (UFT) plus oral leucovorin: 14-day schedule. Investigational New Drugs 15: 123-128, 1997.

5. Diaz-CantÃ³n E and Pazdur R: Preoperative Combined Oral UFT Plus Leucovorin and Radiation Therapy for Rectal Cancer. Oncology 11 (9;10): 58-60, 1997.

6. Pazdur R, Diaz-Canton E, Ballard WP, et al: Phase II Trial of 9-Aminocampothecin (NSC 603071) Administered as a 72-hourÂ Continuous Infusion in Metastatic Colorectal Carcinoma. Journal of ClinicalÂ Oncology 15: 2905-2909. 1997.

7. Pazdur R, Meyers C, Diaz-Canton E, et al: Phase II Trial of Intravenous CI-980 (NSC 370147) in Patients with Metastatic Colorectal Carcinoma: Model for Prospective Evaluation of Neurotoxicity. American Journal of Clinical Oncology 20 (6): 573-6, 1997

8. Diaz-CantÃ³n E, Valero V, Rahman Z, Rodriguez-Monge E, Frye D, Smith T, Buzdar AU, Hortobagyi GN: Clinical course of patients with breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Annals of Oncology 9: 412-418, 1998.

9. Novel targeted agents for the treatment of advanced breast cancer. de la Vega M, DÃaz-CantÃ³n E, Alvarez RH. Future Med Chem. 2012 May;4(7):893-914. doi: 10.4155/fmc.12.45. Review.

10. Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. Recondo G, DÃ¬az Canton E, de la Vega M, Greco M, Recondo G, Valsecchi ME. World J Clin Oncol. 2014 Aug 10;5(3):440-54. doi: 10.5306/wjco.v5.i3.440. Review.

11. Advances and new perspectives in the treatment of metastatic colon cancer. Recondo G Jr, DÃaz-CantÃ³n E, de la Vega M, Greco M, Recondo G Sr, Valsecchi ME. World J Gastrointest Oncol. 2014 Jul 15;6(7):211-24. doi: 10.4251/wjgo.v6.i7.21.

12. Recent treatment advances and novel therapies in pancreas cancer: a review. Valsecchi ME, DÃaz-CantÃ³n E, de la Vega M, Littman SJ. J Gastrointest Cancer. 2014 Jun;45(2):190-201. doi: 10.1007/s12029-013-9561-z. Review.

Book chapters

1. Diaz-CantÃ³n E, Pazdur R: Colorectal Cancer: Diagnosis and Treatment. I Medical Oncology; The Comprehensive Review; Pazdur R (editor); PRR New Jersey; Chapter 17; pp. 263-284, 1995.

2. Coia LR, Bonin SR, Diaz-Canton E, Pazdur R, et al: Esophageal Cancer. In: Cancer: A Multidisciplinary approach; PRR New Jersey, 1996, Chapter 5, pp. 87-95

3. Coia LR, Bonin SR, Diaz-Canton E, Pazdur R, et al: Gastric Cancer. In: Cancer: A Multidisciplinary Approach; PRR New Jersey, 1996, Chapter 6, pp. 96-106.

4. Diaz-Canton E: Chemotherapy in Advanced Colon Cancer. In Cancer 97 Oncology Updates. Manuel GonzÃ¡lez-BarÃ³n (publisher); Banco Bilbao-Vizcaya Foundation, Bilbao, Spain. 1997

5. Diaz-Canton E: Tumors of the Central Nervous System. In: Medicine. Favaloro Foundation. White Mautner (editor). Editorial Center of the Favaloro Foundation. 1998. Chapter 15, pp. 1738-1740.

6. Diaz-Canton E, Peters R: Colon and Rectal Cancer. In: Medicine. Favaloro Foundation. White Mautner (editor). Editorial Center of the Favaloro Foundation. 1998, Chapter 15, pp. 1714-1720.

7. Bonin SR, Coia LR, Hoff PM, Pazdur R, Diaz-Canton EA, and Ellenhorn JDI: Esophageal Cancer. In: Cancer Management: A Multidisciplinary Approach. Second Edition. PRR, Huntington, New York, 1998.

8. Bonin SR, Coia LR, Hoff PM, Pazdur R, Diaz-Canton EA, and Schwarz RE: Gastric Cancer. In: Cancer Management: A Multidisciplinary Approach. Second Edition. PRR, Huntington, New York, 1998.

Research Gate: https://www.researchgate.net/profile/Enrique_Diaz_Canton

Linked In: https://www.linkedin.com/in/enriqued1/?locale=en_US